Relationship between gene polymorphism of IL-28B and clinical, laboratory, virologic parameters in patients with chronic HCV-infection
https://doi.org/10.22625/2072-6732-2014-6-4-19-26
Abstract
For the purpose of clinical laboratory and virologic characteristics of chronic HCV-infection, depending on the gene polymorphisms of IL-28B were examined 104patients. In 70 patients (50 – with genotype 1 and 20 – with genotypes 2 and 3) treated with pegylated interferon-α2a (PIFN) and ribavirin (RBV), evaluated the frequency of sustained virologic response (SVR). According to the results of the study it was found that the patients with HCV had a sufficiently high frequency of registration of «favorable» prognostic single nucleotide polymorphisms (SNPs) rs12979860 CC (23.1%) and rs8099917 TT gene IL-28B (50,9%). On therapy of PIFN and RBV SVR frequency rate in patients with chronic hepatitis C (genotype 1)
and SNPs CC rs12979860 (82,4%) was significantly higher than the efficiency of treatment in patients without this polymorphism (45,5%). In chronic HCV-infection (genotypes 2 and 3) SVR was observed significantly more frequently in patients who have both IL28B CC polymorphism rs12979860, and TT for rs8099917 (88,8%).
About the Authors
K. V. Zhdanov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
D. A. Gusev
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
K. V. Kozlov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
V. S. Sukachyov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
A. V. Shekurov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
S. S. Zhabrov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
D. M. Shakhmanov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
D. V. Berg
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
K. S. Ivanov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
Yu. I. Lyashenko
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
T. M. Zubik
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
References
1. Zhdanov K.V., LobzynYu.V., Gusev D.A., Kozlov K.V. Viral hepatitis. Saint-Petrsburg; 2011 (in Russian).
2. Simankova T.V., Garmash I.V., Arisheva O.S. idr. Klinicheskajafarmakologijaiterapija. 2012; 21 (1):17-22.
3. Zhdanov K.V., Gusev D.A., Kozlov K.V. idr. Zhurnal infektologii. 2012;4 (4): 90-96.
4. Tihonova N.Ju., Burnevich Je.Z. Farmateka. 2012; 2:32- 35.
5. Ge D., Fellay J., Simon A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment – induced viral clearance. Nature. 2009. 461(17): 399-401.
6. Thompson A.J, Muir A.J. Interleukin-28B polymorphism improves viral kinetics and the strongest pretreatment predictor of sustained virological response in genotype 1 hepatitis C virus. Gastroenterology. 2010. 139: 120-129.
7. Micura V.M., Voropaev E.V., Osipkina O.V. idr. Laboratornajadiagnostika. 2012; 2 (2):86-97.
8. Sibbing B., Natterman J. Hepatitis C Virus Infection and Genetic Susceptibility to Therapy. JournalofGastrointestinLiverDises. 2011. 20(4): 397-406.
9. Sjutkin V.E., Chulanov V.P., Karandasheva I.V. i dr. RossijskijzhurnalGastrojenterologii, Gepatologii, Koloproktologii. 2011; 6: 49-56.
10. Bellanti F., G. Vendemiale, E. Altomare The impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C. Clinical and Developmental Immunology. 2012. Vol. 2012: 25-34.
11. Abe H. Il-28B variation affects expression of interferon stimulated genes and Peg-Interferon and ribavirin therapy. Journan of Hepatology. 2011. 54(6) : 1094-1101.
12. Venegas M. Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment. Annals of Hepatology. 2012. 11 (6):827-837.
13. Zhdanov K.V., Gusev D.A., Kozlov K.V. idr. Zhurnalinfektologi. 2011.3(3):100 – 107.
14. Zhdanov K.V., Gusev D.A., Kozlov K.V. idr. Zhurnalinfektologi. 2011. 3(2):74 – 80.
15. Zhdanov K.V., Gusev D.A., Kozlov K.V. idr. Zhurnalinfektologi. 2011. 3(4):116 – 122.
16. Zhdanov K.V.,KozlovK.V., SukachevV.S. Zhurnalinfektologii. 2009. 1(4): 23 – 35.
17. Koljubaeva S.N. [i dr.]. Laboratornoeissledovanieopredelenijapolimorfizmovgenainterlejkina 28B Saint-Petrsburg; 2013 (in Russian).
18. RebrovaO.Ju. Statisticheskij analiz medicinskih dannyh. Primenenie paketa prikladnyh programm STATISTICA. Moscow; 2002 (in Russian).
Review
For citations:
Zhdanov K.V., Gusev D.A., Kozlov K.V., Sukachyov V.S., Shekurov A.V., Zhabrov S.S., Shakhmanov D.M., Berg D.V., Ivanov K.S., Lyashenko Yu.I., Zubik T.M. Relationship between gene polymorphism of IL-28B and clinical, laboratory, virologic parameters in patients with chronic HCV-infection. Journal Infectology. 2014;6(4):19-26. (In Russ.) https://doi.org/10.22625/2072-6732-2014-6-4-19-26
Views:
680
.png)
.png)
Email this article 